HIGHLIGHTS
- who: Hongyu Gong from the bevacizumab, Advanced hepatocellular carcinoma, China have published the Article: Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China, in the Journal: (JOURNAL)
- what: This study provides a cost-effectiveness analysis of these treatments from the patient perspective. From the perspective of the patients, the model showed that sorafenib was linked to the smallest value of QALYs per person (i.e., 1.30) among the four treatment regimens. In this study, a more systematic and comprehensive economic evaluation . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.